Form 4: Precision BioSciences Director Receives RSU Grant

Director Shari Lisa Pire was granted 20,979 restricted stock units by Precision BioSciences, Inc.

Summary

• Director Shari Lisa Pire received a grant of 20,979 restricted stock units (RSUs) on June 3, 2026.
• Each RSU represents a contingent right to receive one share of Precision BioSciences common stock.
• The grant is subject to vesting conditions based on continued service to the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial strategy.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon vesting.

Risks

• Vesting is contingent upon the director's continued service to the issuer.

Future Outlook

The RSUs will vest on the earlier of June 3, 2027, or the day prior to the next annual meeting of stockholders, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard compensation practices for small-cap biotechnology firms.
• The one-year vesting schedule is typical for annual director equity awards.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon the eventual conversion of RSUs to common stock.

Next Steps

• Vesting of the 20,979 RSUs on June 3, 2027, or the day before the next annual meeting.

Key Dates

Keywords

Precision BioSciences, DTIL, Form 4, Insider Trading, Equity Compensation, Director Compensation